Advanced biliary tract cancer represents one of the most challenging gastrointestinal malignancies in China, with increasing ...
Silexion Therapeutics (NASDAQ: SLXN) is advancing precision oncology with a focus on KRAS-driven cancers, among the most challenging targets in oncology. In collaboration with Evonik, Silexion has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback